Trending Down-0.2460 (-4.6154%)
  • Bid / Lots
    5.0700/ 4
  • Ask / Lots
    5.0900/ 2
  • Open / Previous Close
    5.2500 / 5.3300
  • Day Range
    Low 5.0600
    High 5.2700
  • 52 Week Range
    Low 3.9001
    High 23.2150
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 5.33
09:32 ET16265.24
09:34 ET4005.17
09:38 ET11015.16
09:39 ET1005.15
09:41 ET1005.195
09:43 ET3005.16
09:45 ET1625.09
09:52 ET10075.1
09:56 ET1005.11
09:59 ET5005.09
10:06 ET1005.12
10:10 ET1005.12
10:15 ET1005.12
10:17 ET6025.12
10:19 ET3005.16
10:21 ET6005.12
10:24 ET3005.14
10:28 ET1005.2
10:30 ET10005.18
10:32 ET10265.16
10:39 ET9005.19
10:42 ET1285.23
10:46 ET1055.245
10:48 ET1005.26
10:51 ET8825.26
10:53 ET6095.25
10:57 ET3085.27
11:00 ET1005.26
11:04 ET2005.27
11:06 ET3005.26
11:09 ET1035.26
11:11 ET1005.24
11:13 ET3005.22
11:20 ET5005.21
11:22 ET6005.185
11:33 ET11595.165
11:36 ET1005.16
11:42 ET1005.17
11:44 ET2005.155
11:45 ET3015.16
11:47 ET1005.17
11:49 ET3005.16
11:56 ET1005.155
11:58 ET5005.15
12:07 ET8235.13
12:09 ET1005.14
12:12 ET3005.15
12:14 ET4005.15
12:16 ET4365.15
12:20 ET3005.14
12:21 ET2005.14
12:23 ET1005.135
12:25 ET5685.13
12:30 ET1005.115
12:34 ET1005.11
12:38 ET1005.1
12:39 ET2005.1
12:41 ET14035.11
12:45 ET7505.084
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesTIL
Instil Bio Inc
United StatesEWTX
Edgewise Therapeutics Inc
United StatesNKTX
Nkarta Inc
United StatesALT
Altimmune Inc
United StatesIMVT
Immunovant Inc
United StatesGHRS
GH Research PLC
As of 2022-10-07

Company Information

Instil Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte (TIL), therapies for the treatment of patients with cancer. The Company's lead TIL product candidate is ITIL-168, for the treatment of advanced melanoma. ITIL-168, is an autologous TIL therapy that is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. It is also developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform. Its lead CoStAR-TIL product candidate is ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (FOLR1) a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, non-small cell lung cancer (NSCLC) and renal cancer.

Contact Information

3963 Maple Avenue, Suite 350DALLAS, TX, United States 75219


Chairman of the Board, Chief Executive Officer
Bronson Crouch
Chief Financial Officer, Chief Business Officer
Sandeep Laumas
Chief Operating Officer
Timothy Moore
Chief Medical Officer
Zachary Roberts
Lead Independent Director
Neil Gibson

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.